The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Official Title: AN OPEN LABEL, SINGLE ARM PHASE 1B STUDY OF AVELUMAB PLUS AXITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Study ID: NCT03289533
Brief Summary: To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
Detailed Description:
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Iizuka Hospital, Iizuka, Fukuoka, Japan
Kindai University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Kyorin University Hospital, Department of Medical Oncology, Mitaka-shi, Tokyo, Japan
Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan
National Hospital Organization Kyushu Medical Center, Fukuoka, , Japan
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR